BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AP-472 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AP-472\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07432958-1574@assetmemo.bio
DTSTAMP:20261121T005556Z
DTSTART;VALUE=DATE:20270903
DTEND;VALUE=DATE:20270904
SUMMARY:AP-472: Phase 2 readout est. (NCT07432958)
DESCRIPTION:AP-472\, phase 2\, Parkinson's Disease.\nStudy: A Study to Eval
 uate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Lev
 odopa in Parkinson's Disease (PD) Participants With Motor Fluctuations\nEs
 timated primary completion: 3 September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ap-472#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07432958
URL:https://assetmemo.bio/drug/ap-472#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
